Modern approaches to diagnosis and prediction of course of urothelial cancer


Urothelial cancer (UC) holds one of the leading positions amongst oncourological diseases. Rate of cancer is growing all around the world and according to experts the growth rate of cancer is estimated as alarming. Clinical implications of the early disease are so poor that they result in late detection of the decease. Understanding of tumor’s pathogenesis opened the door for development of new approaches for diagnosis of cancer, use of innovative methods and technologies. The modern UC diagnostics includes a variety of lab tests and special exams (invasive method and noninvasive methods). Considering low informative value and limited prospects of these methods, today there are researches in improvement of methods which are already being used and development of new methods for early diagnosis and forecasting of the decease being done. Detecting the most specific, vulnerable and informative markers or its combination of the UC is a pressing topic. In this article we consider questions of peculiarities of structure and site of the UC from all angles; we show directions of the UC phenotype research and results of molecular pan-cancer analysis; new tendencies in the UC classification based on study of genetic profile of the UC’s different forms; a short review of the researched molecular genetic markers of early detection of the UC and prognosticating its progression; prognostic value of somatic mutation in the UC; we evaluate the connection between gene expression, invasion, tumor’s prevalence and survivability in the UC patients; we give some data on our own researches in the UC diagnostics improvement, study of expression of cancer/testis antigen and detection of abnormalities in genetic code in the UC.

About the authors

S V Salnikova

Institute of Immunophysiology; Federal State Budgetary Institution Clinical hospital № 1 under Administrative Directorate of the President of the Russian Federation

Author for correspondence.

T A Slavyanskaya

Institute of Immunophysiology


R I Sepiashvili

Institute of Immunophysiology



  1. Condition of cancer care for Russian population in 2016. Edited by А.D. Kaprin, V.V. Starinskiy, G.V. Petrova, P.A. Herzen. Moscow Scientific and Research Oncological Institute — branch of Federal State Budgetary Institution «National Medical Radiological Research Center» under Russian Ministry of Healthcare. Moscow. 2017. P. 236. (in Russian).
  2. Sobin L.Kh., Gospodarovich М.K., Vittekind K. TNM: Classification of malignant tumors. Translated from English. Edited by N.N. Blinova. St. Petersburg. Aesculapian. 6th Edition. 2003. 244 p. (in Russian)
  3. The Cancer Genome Atlas Research network. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature 2014; 507(7492):315—22.
  4. Eriksson P., Aine M., VeerlaV., Liedberg F., Sjödahl G, Höglund M. Molecular subtypes of urothelial carcinoma are defined by specific gene regulatory systems. BMC Med Genomics 2015;8:25. doi: 10.1186/s12920-015-0101-5.
  5. J. Ryan Mark, Jean Hoffman-Censite and Leonard G. Gomella Basic concepts in immunotherapy for bladder cancer. AJHO. 2017; 13(9):12—17.
  6. Nitu Kumari, Uma S. Dubey, Usha Agrawal. Evolution of Classification Of Bladder (Urothelial) Cancer. Bladder Cancer Classification. NJIRM 2015; Vol. 6(6) Nov — Dec. РР 89—94.
  7. Sjödahl G., Lövgren K., Lauss M., Patschan O., Gudjonsson S., Chebil G., Aine M., Eriksson P., M°ansson W., Lindgren D., Fernö M., Liedberg F., Höglund M. Toward a molecular pathologic classification of urothelial carcinoma. Am. J. Pathol 2013;183(3):681—91.
  8. Choi W., Porten S., Kim S., Willis D., Plimack E.R., Hoffman-Censits J., Roth B., Cheng T., Tran M., Lee I.L., Melquist J., Bondaruk J., Majewski T., Zhang S., Pretzsch S., Baggerly K., Siefker-Radtke A., Czerniak B., Dinney C.P., McConkey D.J. Identification of distinct basal and luminal subtypes of muscle-invasive bladder cancer with different sensitivities to frontline chemotherapy. Cancer Cell. 2014; 25(2):152—65.
  9. Skryabin N.А., Kasevarova А.А., Denisov Е.V., Lebedev I.N. Methods of DNA methylation research: possibilities and prospects of use in oncology. Siberian oncological magazine. 2003. № 6. p. 65—69. (in Russian)
  10. Xylinas E., Cha E., Khani F., Kluth L., Rieken M., Volkmer B., Hautmann R., Küfer R., Chen Y., Zerbib M., Rubin M., Scherr D., Shariat S., Robinson B. Association of oncofetal protein expression with clinical outcomes in patients with urothelial carcinoma of the bladder. J. Urol. 2014 Mar; 191 (3): 830—41.
  11. Hoadley K.A., Yau C., Wolf D.M., Cherniack A.D., Tamborero D., Ng S., Leiserson M.D., Niu B., McLellan M.D., Uzunangelov V., Zhang J., Kandoth C., Akbani R., Shen H., Omberg L., Chu A., Margolin A.A., Van’t Veer L.J., Lopez-Bigas N., Laird P.W., Raphael B.J., Ding L., Robertson A.G., Byers L.A., Mills G.B., Weinstein J.N., Van Waes C., Chen Z., Collisson E.A. Cancer Genome Atlas Research Network, Benz C.C., Perou C.M., Stuart J.M. Multiplatform analysis of 12 cancer types reveals molecular classification within and across tissues of origin. Cell. 2014. Aug 14; 158(4):929—44.
  12. Salnikova S.V., Slavyanskaya T.A. Comparative characteristics of the level of expression of tumor-associated antigens in various forms of invasion of bladder cancer. Int. J. Immunoreh. 2016. Vol. 18. № 2. P. 129.
  13. Slavyanskaya Т.А., Salnikova S.V. Immunological criteria and markers to diagnose and predict bladder cancer. International Journal on Immunorehabilitation. 2009. Vol. 11. № 1. P. 24. (in Russian)
  14. Heim S., Mitelman F. Cancer Cytogenetics: Chromosomal and Molecular Genetic Aberrations of Tumor Cells. Wiley-Blackwell. 2015. 632 p.
  15. Uhlen M., Zhang C., Lee S., Sjöstedt E., Fagerberg L., Bidkhori G., Benfeitas R., Arif M., Liu Z., Edfors F., Sanli K., von Feilitzen K., Oksvold P., Lundberg E., Hober S., Nilsson P., Mattsson J., Schwenk J.M., Brunnström H., Glimelius B., Sjöblom T., Edqvist P.H., Djureinovic D., Micke P., Lindskog C., Mardinoglu A., Ponten F. A pathology atlas of the human cancer transcriptome. Science: 2017 Aug 18; 357(6352).
  16. Slavyanskaya T.A., Salnikova S.V., Sepiashvili R.I. Chromosome aberrations and the expression of tumor-associated antigens by tumor cultures of bladder cancer with long-term cultivation. Int. J. Immunoreh. 2016. Vol. 18. № 2. P. 128—129.
  17. Owen T.M. Chan, Hideki Furuya, Ian Pagano, Yoshiko Shimizu, Kanani Hokutan, Lars Dyrskjøt, Jørgen Bjerggaard Jensen, Per-Uno Malmstrom, Ulrika Segersten, Filip Janku, Charles J. Rosser. Association MMP-2, RB and PAI-1 with reduced survival without relapse and overall survival in patients with bladder cancer. Oncotarget. 2017. Nov. 21; 8 (59): 99707—21.
  18. Daniel S. Chen, Bryan A. Irving and F. Stephen Hodi. Molecular Pathways: Next-Generation Immunotherapy-Inhibiting Programmed Death-Ligand 1 and Programmed Death-1. Clin. Cancer Res. Dec. 15, 2012. Vol. 18. N. 24. Р. 6580—88.
  19. Salnikova S.V., Slavyanskaya Т.А. Comparative analysis of tumor-associated antigen’s expression level at different invasion types of bladder cancer. Allergology and Immunology. 2016. Vol. 17. № 4. P. 258. (in Russian)
  20. Yoshimoto R., Mayeda A., Yoshida M., Nakagawa S. MALAT1 long non-coding RNA in cancer. Biochim Biophys Acta. 2016 Jan; 1859 (1): 192—9.
  21. Deng Hou, Lijia Zhou, Longwang Wang, Gallina Kazobinka, Xiaoping Zhang, and Zhaohui Chen. CLCA4 inhibits proliferation, migration, and invasion of bladder cancer cells by inhibiting the PI3K/AKT pathway. Oncotarget. 2017. Nov.3; 8 (54): 93001—93013.
  22. Zhang E., Gu J., Xu H. Prospects for chimeric antigen receptor modified T cell therapy for solid tumors. Molecular Cancer (2018) 17:7. doi: 10.1186/s12943-018-0759-3.
  23. McGowan-Jordan J., Simons A., Schmid M. ISCN: an international system for human cytogenomic nomenclature. Basel, New York: Karger. 2016. 140 p.
  24. Ali Ghasemzadeh, Trinity J. Bivalacqua, Noah M. Hahn, and Charles G. Drake New Strategies in Bladder Cancer: A Second Coming for Immunotherapy. Clin. Cancer Res. 2016. Feb. 15; 22 (4): 793—801.
  25. Venkatrao Vantaku, Sri Ramya Donepudi, Chandrashekar R. Ambati, Feng Jin, Vasanta Putluri, Khoa Nguyen, Kimal Rajapakshe, Cristian Coarfa, Venkata Lokesh Battula, Yair Lotan, Nagireddy Putluri. Expression of ganglioside GD2, reprogram the lipid metabolism and EMT phenotype in bladder cancer. Oncotarget. 2017 Nov 10; 8 (56): 95620—31.



Abstract - 533

PDF (Russian) - 210




Copyright (c) 2018 Salnikova S.V., Slavyanskaya T.A., Sepiashvili R.I.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies